Fujifilm India launches the next phase of its TB campaign

The proposed districts in this phase are Sonitpur, Golaghat, Jorhat, Sivasagar, Dibrugarh, Tinsukia, in Assam, Wayanad in Kerala, and Kutch district in Gujarat starting September 2022 and conclude by August 2023

Fujifilm India has launched the second phase of its campaign on TB “Never Stop: Screening To Reduce Diagnostic Delays”. The second phase of this campaign aims to increasing awareness on TB as a curable disease and promote screening and early diagnosis among tea sector workers, difficult to reach population in rural and urban areas including tribal population in selected districts of Gujarat, Kerala and Assam. Under the campaign, Fujifilm India will support three mobile hand held X-ray machines and implementation of project in community settings

Fujifilm aims to reach to more than 5 million people and screen around 30,000 of them by using the handheld X-ray machines. The project will also facilitate TB testing of identified presumptive cases. In association with International Union Against TB and Lung Disease (The Union), the project aims to demonstrate a model on promoting early diagnosis for TB by utilising newer solutions in community settings. Through the campaign, Fujifilm will be offering door-to-door awareness on TB and provide mobile digital X-ray services along with Qure.ai’s computed aided radiology software application designed with deep-learning for the intervention.

The proposed districts in this phase are Sonitpur, Golaghat, Jorhat, Sivasagar, Dibrugarh, Tinsukia, in Assam, Wayanad in Kerala, and Kutch district in Gujarat starting September 2022 and conclude by August 2023.

In the first phase, Fujifilm India screened over one million people and shared around 8,000 X-ray reports. Through the intervention, 117 new TB patients were identified across 27 cities including Delhi, Dadri, Dehradun, Haridwar, Haldwani, Rudrapur, Patna, Jaipur, Indore, Kolkata, Raipur, Pata, etc.

 

 

Fujifilm IndiaTB and Lung DiseaseTB screening
Comments (0)
Add Comment